• I don’t know where else you would find an investment bank with such expertise. They could move from financial and strategic discussions to highly scientific, clinical discussions with ease. In the end, they brought all these perspectives to bear, developing an exceptional strategy that created value for our company.

    Herb Stern CEO, Colonary Concepts

  • Outcome Capital has demonstrated an astute and insightful understanding of our value proposal and the major companies in the cardiovascular space. They provided us with invaluable strategic advice and I can’t think of better partners to have guided us through the process.

    Alex Martin President & CEO, Coherex Medical

  • They understood our technology and business as well as anyone.

    Victor Esch, PhD President & CEO, DNAe

  • Outcome worked diligently with our executives and board to develop and communicate a strategy that was instrumental in enhancing the value of our company. Their business acumen and knowledge of our market space drove a complex transaction to a very successful close.

    Lisa Dunlea CEO, XableCath

  • Advanced Uro-Solutions engaged the services of Outcome Capital late in the process of being acquired. Outcome Capital took control of all further negotiations and masterfully increased the value of our final offering. The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner. Arnie and Oded brought an amazing team of talented, organized and highly effective individuals. We could NOT have been more satisfied.

    John D Green, MD CEO, Advanced Uro-Solutions

  • With the assistance of Outcome’s recognized expertise in the biomedical field, GenePOC was able to devise and communicate a market-aligned strategy leading to the completion a transaction efficiently and effectively. We are very pleased with the way Outcome supported us throughout this process.

    Patrice Allibert, PhD CEO, GenePOC

  • I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.

    Sami El-Saden Chairman and CEO, Verrix

  • As a dedicated life sciences investment banking group, Outcome leveraged their industry knowledge in positioning BHA in the market and deftly communicated the value we offer our clients to our transaction partner. Their ability to execute alone was worth their value, considering the volume of work they took on, but as a CEO it was their patient demeanor balanced by their tenacious attitude that I will remember and benefitted from most. By the end of the transaction, I was thankful for each member of our deal team at Outcome Capital and the value they offered.

    Joseph Ferrara CEO, Boston Healthcare Associates

Outcome Capital has witnessed the accelerated adoption of technology within our healthcare system to more efficiently coordinate patient care and integrate key stakeholders, including providers and payers.

The healthcare system must balance the demands of its many stakeholders, including patients, insurers, and providers. Recent technology advances present an opportunity to make healthcare more efficient and accessible – from increasing data collection to improving analytics/diagnosis to coordinating and delivering care virtually. The Outcome Capital Healthcare team is dedicated to understanding the many intricacies and ongoing advancements to anticipate segment trends dynamics. The healthcare operational experience of Outcome professionals enables effective positioning to maximize value for their clients across M&A, capital raise and advisory services.

  • Digital Health
  • Healthcare IT
  • Telemedicine / Remote Patient Monitoring
  • Tech-Enabled Payers
  • Healthcare Services

View Resources

Featured Transactions

Has sold its business to

The undersigned acted as the exclusive strategic & financial advisor to Verrix, LLC

Has sold its business to

Exclusive Strategic & Financial Advisor to Boston Healthcare Associates, Inc.

Has Acquired

GenePOC
Exclusive Financial Advisor to GenePOC

Has Sold Its Business To

Exclusive Financial Advisor to Beryllium

Has Sold Its Business To

Exclusive Financial Advisor to ColonaryConcepts

Has Sold Its Business To

Exclusive Financial Advisor to Advanced Uro-Solutions

Has Issued 5,000,000 Shares of Series A Preferred Stock

Exclusive Financial Advisor to Predictive Therapeutics

Has Sold Its Business To

Exclusive Financial Advisor to Coherex Medical

Completed Its Debt & Equity Financing & Distribution Agreement With

Exclusive Financial Advisor to Ember Therapeutics

Has Sold Its Business To

Exclusive Financial Advisor to nanoMR

Has Completed an Option Deal and Financing Led By

Exclusive Financial Advisor to IRX Therapeutics

Has Sold Its Business To

Exclusive Financial Advisor to angiolink

$60,000,000 Series C Financing By a Group Led By

Exclusive Financial Advisor to Dicerna Pharmaceuticals

$15,000,000

Exclusive Financial Advisor to Pure Life Renal

$49,000,000 Histogenics Series A Preferred Investment From a Group Co-led by

Exclusive Placement Agent for Histogenics

Has Sold Its Business To

Exclusive Financial Advisor to Bioscan

$9,000,000 Series B Preferred Investment From a Group Led by

Exclusive Placement Agent for Histogenics

$5,900,000 Spirus Medical Series A Preferred Investment From a Group Co-led by

Exclusive Placement Agent for Spirus Medical

Has Sold Its Business To

Exclusive Financial Advisor to Prochon Biotech

$5,300,000 Series A Preferred Investment From

Exclusive Placement Agent for arthosurface

$13,600,000 Series B Convertible Preferred Investment From a Group Led by

Exclusive Placement Agent for angiolink

$13,100,000 Series A1 Preferred Investment From a Group Led by

Exclusive Placement Agent for Histogenics

Has Sold Its Business To

Exclusive Financial Advisor to Claros Diagnostics

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-4886